Screener
Veracyte VCYT Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,791,856 and 79,359,005 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 80 | 79 |
| Additional paid-in capital | 1,701,470 | 1,695,339 |
| Accumulated deficit | (348,923) | (377,630) |
| Accumulated other comprehensive loss | (8,221) | (8,212) |
| Total stockholders’ equity | 1,344,406 | 1,309,576 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's common stock?
- Veracyte (VCYT) reported common stock of 125M in Q1 2026.
- How has Veracyte's common stock changed year-over-year?
- Veracyte's common stock decreased by 0.0% year-over-year, from 125M to 125M.
- What is the long-term trend for Veracyte's common stock?
- Over 5 years (2020 to 2025), Veracyte's common stock has grown at a 364.2% compound annual growth rate (CAGR), from 58K to 125M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Veracyte's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude